A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
MD Anderson Study Status
Tucatinib, Trastuzumab, Capecitabine
A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Metastatic Breast Cancer, Leptomeningeal Disease
Breast Medical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.